# Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.

> PubMed lists PMID 40555685 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2025-06-24 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40555685-dulaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40555685-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40555685-dulaglutide-v1.json
- Content SHA-256: `4585c61534433aa3b5dc07dad5948636eabeb3204851d5d17c086d9514d07578`

## Claims and source pins

### Headline

Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand. ([`pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5`](#source-pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5))

### Summary

PubMed lists PMID 40555685 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2025-06-24 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5`](#source-pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5))

### Paragraph 1

PubMed lists PMID 40555685 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2025-06-24 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5`](#source-pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5`](#source-pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5))

## Sources

<a id="source-pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5"></a>
- **Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand. · retained source version 1:2025-09-11:current:f5bf2127dcc555ad8e0ed58dd45a603534158f4cc97b6d306d6f7cc2312041d7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40555685/) (`pubmed-observation-pmid-40555685-2025-09-11-f5bf2127dcc5`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40555685-dulaglutide-v1.json SHA-256: 4585c61534433aa3b5dc07dad5948636eabeb3204851d5d17c086d9514d07578.